Course Opens
12/05/2024 at 12:00 PM EST
Credits
1
Credit Expires
02/05/2025
The treatment paradigm in bladder cancer has fundamentally changed over the past decade, and the evolving, dense clinical trial landscape has given rise to barriers to optimizing patient care. This Community Connections Grand Rounds series will focus on emerging trial data for antibody-drug conjugates (ADCs); sequence optimization, combinatorial therapy utilization, and identification of when and in which patients to use ADCs; and anticipation, recognition, and management of treatment-related adverse events (TRAEs) in patients with metastatic urothelial cancer (mUC).
Join our expert faculty for this 60-minute activity designed to help clinicians stay abreast of emerging trial data and evolving treatment guidelines, as well as effectively manage agent-specific AEs, to optimize care for their patients with mUC.
At the conclusion of this activity, learners will be able to better:
This program has been supported by an independent educational grant from Gilead Sciences, Inc.
Community oncologists, urologists, physician associates (PAs), oncology nurse practitioners (NPs), nurses, and pharmacists
In support of improving patient care, Creative Educational Concepts, LLC, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Creative Educational Concepts, LLC, designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This application-based activity is approved for 1.00 contact hours (0.1 CEUs) of continuing pharmacy credit (JA0007101-0000-24-015-L01-P).
This activity is designated for 1.00 contact hours.
Note to Nurse Practitioners: The content of this CNE activity pertains to Pharmacology.
This activity is designated for 1.00 contact hours.
The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points in the following ILNA subject areas:
OCN®
Care Continuum
Oncologic Emergencies
Oncology Nursing Practice
Symptom Management, Palliative Care, Supportive Care
Treatment
AOCNP®/AOCNS®
Care Continuum
Oncologic Emergencies
Symptom Management, Palliative Care, Supportive Care
Treatment
CPHON®
Care Continuum
Oncologic Emergencies
Symptom Management, Palliative Care, Supportive Care
Treatment
CBCN®
Care Continuum
Treatment
This activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education Credit for learning and change.
Creative Educational Concepts, LLC, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.00 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Faculty
Dr. Dreicer, reports the following financial relationships:
Advisory Board: Astellas Pharma Inc.; Bayer; Gilead Sciences, Inc.; MacroGenics, Inc.; and Pfizer Inc.
Consultant: Merck & Co., Inc.
Research Support: Arvinas and Exelixis, Inc.
Planners
Dr. Petros Grivas, MD, PhD, reports the following financial relationships:
Consulting/Advisory Role: Aadi Bioscience; Abbvie Inc.; Asieris Pharmaceuticals; Astellas Pharma Inc.; AstraZeneca; Bristol Myers Squibb Company; Bicycle Therapeutics; CG Oncology; EMD Serono; Fresenius Kabi; G1 Therapeutics, Inc.; Gilead Sciences, Inc.; ImmunityBio, Inc.; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; Pfizer Inc.; Roche; and Strata Oncology, Inc.
Research Funding: (paid to institution): Acrivon Therapeutics; ALX Oncology Inc.; Bristol Myers Squibb Company; EMD Serono; G1 Therapeutics, Inc.; Genentech, Inc.; Gilead Sciences, Inc.; Merck & Co., Inc.; Mirati Therapeutics, Inc.; and QED Therapeutics
Dr. Daniel P. Petrylak, MD, reports the following financial relationships:
Consultant: Advanced Accelerator Applications; Amgen Inc.; Astellas Pharma Inc.; AstraZeneca; Bayer; Bicycle Therapeutics; Boehringer Ingelheim; Bristol Myers Squibb Company; Clovis Oncology; Lilly; Exelixis, Inc.; Gilead Sciences, Inc.; Incyte; Infinity Pharmaceuticals, Inc.; Ipsen Pharma; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; Mirati Therapeutics, Inc.; Monopteros Therapeutics, Inc.; Pfizer Inc.; Pharmacyclics; Regeneron Pharmaceuticals Inc.; Roche; Sanofi; Seattle Genetics, Inc.; and UroGen Pharma, Inc.
Grant/Research Support: Adlai Nortye Ltd.; Advanced Accelerator Applications; Agensys, Inc.; Arvinas; Astellas Pharma Inc.; AstraZeneca; Bayer; BioXcel Therapeutics, Inc.; Bristol Myers Squibb Company; Clovis Oncology; Daiichi Sankyo Company, Limited; Eisai; Lilly; Endocyte, Inc.; Ferring Pharmaceuticals; Genentech, Inc.; Gilead Sciences, Inc.; Innocrin Pharmaceuticals Inc.; MacroGenics, Inc.; MedImmune; Medivation, Inc.; Merck & Co., Inc.; Mirati Therapeutics, Inc.; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Progenics Pharmaceuticals, Inc.; Replimune Group Inc.; Roche; Sanofi, and Seattle Genetics, Inc.
Ms. Terran W. Sims MSN, ACNP-C, CNN, COCN-C, reports the following financial relationships:
Consultant: Coloplast US Ostomy
The following individuals have no financial relationships to disclose:
Rebecca Vargas-Jackson, MD (Peer Reviewer)
Elizabeth Naber, MSN, RN, CCRN-K, CNRN, TCRN (Peer Reviewer)
David Modrak, PhD (Planning Committee)
Katherine E. Lee, PharmD, MPH (Planning Committee)
Nichole Lainhart (Planning Committee)
Scott J. Hershman, MD, FACEHP, CHCP (Planning Committee)
Sandra Caballero, PharmD (Planning Committee)
Sharon Tordoff (Planning Committee)
Post-tests, credit request forms, and activity evaluations must be completed online
(requires free account activation), and participants can print their certificate or statement of
credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac.
Visit the Creative Educational Concepts Privacy Policy page for complete information about our privacy policy and practices.
Call us at 859-260-1717 • info@ceconcepts.com
GR-051
Call us at 859-260-1717 • info@ceconcepts.com
